Senator questions Merck over patent strategy for blockbuster cancer drug Keytruda

Senator Maggie Hassan is questioning Merck about its patent and pricing practices for the cancer drug Keytruda, alleging the company uses excessive patents to delay cheaper alternatives. The letter highlights concerns that Merck's strategies have kept prices high and limited patient access, with an investigation suggesting the new injectable version could delay competition until the 2030s.